Business Description
Adverum Biotechnologies Inc
NAICS : 325412
SIC : 2834
ISIN : US00773U1088
Description
Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.09 | |||||
| Equity-to-Asset | 0.62 | |||||
| Debt-to-Equity | 0.51 | |||||
| Debt-to-EBITDA | -0.74 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -5.91 | |||||
| Beneish M-Score | -3.1 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 4.2 | |||||
| 3-Year EPS without NRI Growth Rate | 5.6 | |||||
| 3-Year FCF Growth Rate | 5.3 | |||||
| 3-Year Book Growth Rate | -43 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 26.98 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 17.06 | |||||
| 9-Day RSI | 24.22 | |||||
| 14-Day RSI | 28.92 | |||||
| 6-1 Month Momentum % | -57.84 | |||||
| 12-1 Month Momentum % | -16.91 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.82 | |||||
| Quick Ratio | 5.82 | |||||
| Cash Ratio | 5.54 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.3 | |||||
| Shareholder Yield % | -102.18 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -10310 | |||||
| Net Margin % | -9411.1 | |||||
| FCF Margin % | -8755.16 | |||||
| ROE % | -69.14 | |||||
| ROA % | -41.8 | |||||
| ROIC % | -113.57 | |||||
| ROC (Joel Greenblatt) % | -157.16 | |||||
| ROCE % | -51.53 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 98.75 | |||||
| PB Ratio | 0.68 | |||||
| Price-to-Tangible-Book | 0.68 | |||||
| EV-to-EBIT | -0.18 | |||||
| EV-to-Forward-EBIT | -0.12 | |||||
| EV-to-EBITDA | -0.19 | |||||
| EV-to-Forward-EBITDA | -0.12 | |||||
| EV-to-Revenue | 18.63 | |||||
| EV-to-Forward-Revenue | 43.22 | |||||
| EV-to-FCF | -0.22 | |||||
| Price-to-Net-Current-Asset-Value | 1.4 | |||||
| Price-to-Net-Cash | 1.56 | |||||
| Earnings Yield (Greenblatt) % | -555.56 | |||||
| FCF Yield % | -87.28 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Adverum Biotechnologies Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.901 | ||
| EPS (TTM) (€) | -5.505 | ||
| Beta | -0.59 | ||
| Volatility % | 118.85 | ||
| 14-Day RSI | 28.92 | ||
| 14-Day ATR (€) | 0.22826 | ||
| 20-Day SMA (€) | 5.4075 | ||
| 12-1 Month Momentum % | -16.91 | ||
| 52-Week Range (€) | 4.44 - 25.2 | ||
| Shares Outstanding (Mil) | 20.8 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Adverum Biotechnologies Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Adverum Biotechnologies Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Adverum Biotechnologies Inc Frequently Asked Questions
What is Adverum Biotechnologies Inc(STU:AVU0)'s stock price today?
The current price of STU:AVU0 is €4.44. The 52 week high of STU:AVU0 is €25.20 and 52 week low is €4.44.
When is next earnings date of Adverum Biotechnologies Inc(STU:AVU0)?
The next earnings date of Adverum Biotechnologies Inc(STU:AVU0) is 2025-03-18 Est..
Does Adverum Biotechnologies Inc(STU:AVU0) pay dividends? If so, how much?
Adverum Biotechnologies Inc(STU:AVU0) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers